Does paired genetic testing improve targeted therapy choices and screening recommendations for patients with upper gastrointestinal cancers and their families? A prospective cohort of 42 patients
More than 75% of patients who received tumour testing were eligible for a targeted therapy regardless of their stage at diagnosis, emphasising the need to expand access to testing with staging workup to improve survival outcomes. Six families received personalised screening recommendations, thanks to this study.
Authors
- Lauren A. Facchini
- Mercy Laurino (ORCID: https://orcid.org/0000-0001-7152-5048)
- Veena Shankaran (ORCID: https://orcid.org/0000-0001-8136-6140)
- Angela Jacobson (ORCID: https://orcid.org/0000-0002-6565-1459)
- Eric Q. Konnick
- Qin Sun (ORCID: https://orcid.org/0000-0002-8270-3943)
- Cynthia Handford
- Stacey A. Cohen (ORCID: https://orcid.org/0000-0002-6207-9856)
- William M. Grady (ORCID: https://orcid.org/0000-0002-0129-7809)
- Brant K. Oelschlager (ORCID: https://orcid.org/0000-0003-2231-5575)
- Lorraine Naylor
- Marianne Dubard-Gault (ORCID: https://orcid.org/0000-0002-5735-1819)
- Britta Sjoding
- Everett Lally
- Kevin Tatunay
- Colin C. Pritchard
Institutions
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Swedish Medical Center (US)
- Swedish Medical Center (US)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-091745
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00